Search results for "Placebo"

showing 10 items of 704 documents

Effects of red orange juice intake on endothelial function and inflammatory markers in adult subjects with increased cardiovascular risk

2012

BACKGROUND Oxidative and inflammatory stresses are involved in the pathogenesis of atherosclerosis. The consumption of fruit and vegetables is associated with improved health and reduced cardiovascular risk. Red oranges have a high content of antioxidant and antiinflammatory substances, but there is a paucity of data concerning their effects on cardiovascular biomarkers in subjects with increased cardiovascular risk. OBJECTIVE We investigated the effect of red orange juice intake on endothelial function, oxidative stress, and markers of inflammation in subjects with increased cardiovascular risk. DESIGN Nineteen nondiabetic subjects with increased cardiovascular risk (aged 27-56 y) were inc…

AdultMalemedicine.medical_specialtyEndotheliumAnti-Inflammatory AgentsMedicine (miscellaneous)Inflammationmedicine.disease_causePlaceboAntioxidantsBeveragesYoung AdultRisk FactorsInternal medicineDiabetes mellitusDiabetes MellitusmedicineBody Fat DistributionHumansSingle-Blind MethodEndotheliumSettore MED/49 - Scienze Tecniche Dietetiche Applicateendothelial function cardiovascular risk red oranges inflammation FMDAgedInflammationOrange juiceCross-Over StudiesNutrition and DieteticsbiologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryC-reactive proteinMiddle Agedmedicine.diseaseCrossover studyOxidative StressC-Reactive ProteinEndocrinologymedicine.anatomical_structureCardiovascular DiseasesFruitbiology.proteinFemalemedicine.symptombusinessBiomarkersOxidative stressCitrus sinensis
researchProduct

Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans.

2010

Objectives We aimed to assess whether concurrent administration of atorvastatin would modify the development of tolerance and endothelial dysfunction associated with sustained nitroglycerin (GTN) therapy in humans. Background Animal studies have demonstrated that administration of 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors can protect against GTN-induced endothelial dysfunction and tolerance, likely through an antioxidant mechanism. Methods Thirty-six healthy male volunteers were randomized to receive continuous transdermal GTN (0.6 mg/h) and placebo, atorvastatin (80 mg/day) alone, or continuous transdermal GTN (0.6 mg/h) with concurrent atorvastatin (80 mg/day), all for 7 …

AdultMalemedicine.medical_specialtyEndotheliumendotheliumAdolescentBrachial Arterymedicine.medical_treatmentAtorvastatinVasodilator AgentsBlood PressurePlaceboNitroglycerinYoung AdultDouble-Blind MethodHeart RateReference ValuesInternal medicinemedicineAtorvastatinHumansPyrrolesEndothelial dysfunctionSalinetolerancebiologybusiness.industryDrug Administration RoutesDrug Tolerancemedicine.diseaseVasodilationOxidative StressBlood pressuremedicine.anatomical_structureEndocrinologyHeptanoic AcidsCirculatory systemHMG-CoA reductasebiology.proteincardiovascular systemlipids (amino acids peptides and proteins)Endothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusinessmedicine.drugcirculatory and respiratory physiologyJournal of the American College of Cardiology
researchProduct

Mealtime versus nighttime acid inhibition

1992

This study was carried out in order to compare the effects of mealtime and bedtime regimens of ranitidine on gastric acidity. Fifteen duodenal ulcer patients in clinical remission were randomized to receive in single-blind fashion either placebo, ranitidine 300 mg at night (2200 hr) or ranitidine 150 mg three times a day given before each of the three daily meals (1800, 0800 and 1200 hr). Over 24 hr, the two active treatments produced a significantly greater acid inhibition than placebo, while the single daily regimen was superior to the three times a day regimen of ranitidine in terms of both rise in pH values (P less than 0.001) and duration of action expressed as time spent above 3.0 pH …

AdultMalemedicine.medical_specialtyEveningPhysiologyRanitidinePlaceboBedtimeGastroenterologyDrug Administration ScheduleRanitidineEatingHistamine H2 receptorInternal medicinemedicineHumansSingle-Blind MethodCircadian rhythmGastric Acidity Determinationbusiness.industryGastroenterologyGastric Acidity DeterminationMiddle AgedCircadian RhythmRegimenEndocrinologyDuodenal UlcerFemalebusinessmedicine.drugDigestive Diseases and Sciences
researchProduct

Reduction of negative alliesthesia for sweet gustatory stimuli by cyproheptadine, a serotonin antagonist

1990

Cyproheptadine (CH) is a serotonin antagonist that increases food intake and body weight. In order to elucidate its mechanism of action on the control of food intake, hunger ratings, pleasure-displeasure to sweet gustatory stimuli and negative alliesthesia induced by a 50 g glucose load were compared in 14 healthy subjects after they had received a placebo or 16 mg of CH. Cyproheptadine did not affect the hunger rating, nor the affective rating in fasted subjects, but it reduced significantly the negative alimentary alliesthesia induced by the glucose load. It was concluded that CH increases food intake more by reducing satiation than by increasing hunger. This is in line with the anti-sero…

AdultMalemedicine.medical_specialtyFood intakeCyproheptadineSatiationAlliesthesiaCyproheptadinePlaceboSatiety ResponseGeneral Biochemistry Genetics and Molecular BiologyEatingRandom AllocationInternal medicinemedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsAnalysis of VarianceMotivationbusiness.industrydigestive oral and skin physiologyAntagonistHealthy subjectsGeneral MedicineMiddle AgedGlucoseEndocrinologyMechanism of actionTasteFemaleSerotoninmedicine.symptombusinessmedicine.drugLife Sciences
researchProduct

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

2019

###EgeUn###

AdultMalemedicine.medical_specialtyHerpes Zoster Vaccinemedicine.medical_treatmentvirusesVaccines Synthetic/administration & dosageHematopoietic stem cell transplantationPlaceboInjections IntramuscularTransplantation Autologous01 natural sciencesHerpes Zoster Vaccine/administration & dosage03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationAdjuvants ImmunologicInternal medicinehemic and lymphatic diseasesmedicineHumansSingle-Blind Method030212 general & internal medicine0101 mathematicsAdverse effectHospitalization/statistics & numerical dataProportional Hazards ModelsImmunocompromised hostintegumentary systembusiness.industryIncidence (epidemiology)010102 general mathematicsvirus diseasesGeneral MedicineMiddle AgedNeuralgia Postherpetic/prevention & controlTransplantationsurgical procedures operativeHerpes Zoster/epidemiologyhematopoietic stem cell transplantationoncologyincidenceFemaleZoster vaccinebusinessFollow-Up Studiesmedicine.drug
researchProduct

Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury.

2013

PCSK9 (proprotein convertase subtilisin kexin type 9) is a secreted protease that modulates cholesterol homeostasis by decreasing low-density lipoprotein receptor expression. Low levels of plasma lipoproteins are related to severity of illness and survival in patients of intensive care units (ICU).The aim of the study was to investigate the regulation of plasma PCSK9 and its association with plasma lipid parameters and clinical markers of severity during critical illness.The plasma biobank from the previously published HYPOLYTE prospective study was used to measure PCSK9 concentrations by ELISA at days 0 and 8 in 111 patients admitted to surgical ICU for severe multiple trauma. Patients wer…

AdultMalemedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismReceptor expressionCritical IllnessClinical BiochemistryContext (language use)PlaceboBiochemistryGastroenterologySeverity of Illness IndexPlacebosEndocrinologyIntensive careInternal medicineSeverity of illnessmedicineHumansProspective cohort studyInfusion PumpsHydrocortisoneTrauma Severity Indicesbusiness.industryPCSK9Biochemistry (medical)Serine EndopeptidasesCholesterol LDLPrognosisIntensive Care UnitsEndocrinologyImmunologyWounds and InjuriesFemaleProprotein ConvertasesProprotein Convertase 9businessBiomarkersmedicine.drugThe Journal of clinical endocrinology and metabolism
researchProduct

The Influence of Treatment Expectations on Clinical Outcomes and Cortisol Levels in Patients With Chronic Neck Pain: An Experimental Study

2019

Background The role of contextual factors like pre‐existing treatment expectations has been established. However, the effect of verbally delivered treatment expectations in patient–therapist communication has not been considered, nor has the role of cortisol changes within the placebo/nocebo response in people with chronic neck pain. Objective To examine the effect of verbally delivered treatment expectations on clinical outcomes in physical therapy practice and to determine if changes in cortisol levels are associated with changes in neck pain and disability. Methods Eighty‐three patients with chronic neck pain were randomly allocated to 3 different verbally delivered expectations (positiv…

AdultMalemedicine.medical_specialtyHydrocortisoneNoceboPsychological interventionPlacebo03 medical and health sciencesChronic neck pain0302 clinical medicine030202 anesthesiologyHumansMedicineNocebo EffectCortisol levelPhysical Therapy ModalitiesMotivationNeck painNeck Painbusiness.industryChronic painMiddle Agedmedicine.diseaseNocebo EffectAnesthesiology and Pain MedicinePhysical therapyFemaleChronic Painmedicine.symptombusiness030217 neurology & neurosurgeryPain Practice
researchProduct

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc-related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3-week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

AdultMalemedicine.medical_specialtyImmunologyPhases of clinical researchSelexipagPlaceboSeverity of Illness Indexlaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodRheumatologyRandomized controlled triallawInternal medicineAcetamidesSeverity of illnessClinical endpointHumansImmunology and AllergyMedicine030212 general & internal medicineAdverse effectAntihypertensive Agents030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryBayes TheoremRaynaud DiseaseMiddle AgedClinical trialTreatment OutcomechemistryPyrazinesFemalebusiness
researchProduct

Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary fin…

2007

The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group I (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and C…

AdultMalemedicine.medical_specialtyIndomethacinPlaceboGastroenterologyElectrocardiographyPericarditisAcute pericarditisDouble-Blind MethodRecurrenceInternal medicineTroponin ImedicineHumansPericarditisRosuvastatinRosuvastatin CalciumPericarditis Colchicine Postpericardiotomy syndromeFirst episodeSulfonamidesmedicine.diagnostic_testbiologybusiness.industryAnti-Inflammatory Agents Non-SteroidalCardiovascular AgentsGeneral Medicinemedicine.diseaseSurgeryFluorobenzenesC-Reactive ProteinPyrimidinesTreatment OutcomeErythrocyte sedimentation rateAcute Diseasebiology.proteinDrug Therapy CombinationFemaleCreatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsbusinessFollow-Up Studiesmedicine.drugClinical Science
researchProduct

Influence of loperamide and loperamide oxide on the anal sphincter

1992

The objective of this study was to investigate the effects of the opioid loperamide and its recently synthesized pharmacologically inactive prodrug loperamide oxide on the anal sphincter. In a double-blind, placebo-controlled crossover study, anorectal manometry was performed in 12 healthy volunteers five hours after oral bolus application of 10 mg of loperamide, loperamide oxide, or placebo. Loperamide significantly increased the threshold volumes for minimal perception and urgency to defecate (P less than 0.05) and raised the volume required to abolish recovery of the rectoanal inhibitory reflex (P less than 0.05). These findings suggest that loperamide has a specific continence-improving…

AdultMalemedicine.medical_specialtyLoperamideManometryAnal CanalPlaceboLoperamideGastroenterologyBolus (medicine)Double-Blind MethodInternal medicinePressuremedicineHumansDefecationbusiness.industryAnorectal manometryRectumGastroenterologyGeneral MedicineProdrugCrossover studyOpioidDefecationFemalebusinessmedicine.drugDiseases of the Colon & Rectum
researchProduct